4 224

Cited 0 times in

Changes in serum levels of cartilage oligomeric matrix protein after estrogen and alendronate therapy in postmenopausal women.

Authors
 Seok Kyo Seo  ;  Hyo In Yang  ;  Kyung Jin Lim  ;  Young Eun Jeon  ;  Young Sik Choi  ;  SiHyun Cho  ;  Byung Seok Lee 
Citation
 GYNECOLOGIC AND OBSTETRIC INVESTIGATION, Vol.74(2) : 143-150, 2012 
Journal Title
 GYNECOLOGIC AND OBSTETRIC INVESTIGATION 
ISSN
 0378-7346 
Issue Date
2012
MeSH
Aged ; Alendronate/therapeutic use* ; Androstenes/therapeutic use ; Bone Density ; Bone Density Conservation Agents* ; Bone Diseases, Metabolic/drug therapy ; Cartilage/drug effects ; Cartilage/physiopathology ; Cartilage Oligomeric Matrix Protein ; Estradiol/therapeutic use* ; Extracellular Matrix Proteins/blood* ; Female ; Glycoproteins/blood* ; Humans ; Matrilin Proteins ; Middle Aged ; Mineralocorticoid Receptor Antagonists ; Osteoarthritis/prevention & control ; Osteocalcin/blood ; Osteoporosis, Postmenopausal/drug therapy* ; Postmenopause/physiology*
Keywords
Cartilage oligomeric matrix protein ; Osteoarthritis ; Estrogen ; Alendronate ; Menopause
Abstract
BACKGROUND: Cartilage oligomeric matrix protein (COMP) is a biomarker for joint destruction and its serum levels are used for assessing therapeutic efficacy. This study aims to compare changes in serum COMP levels in postmenopausal women with osteopenia/osteoporosis receiving estrogen and alendronate. METHODS: A total of 62 postmenopausal women diagnosed with osteopenia or osteoporosis were treated with either estrogen (17β-estradiol 1 mg, n = 30) or bisphosphonate (alendronate 5 mg, n = 32) for 6 months. The controls were healthy postmenopausal women (n = 30). Serum COMP and osteocalcin levels were measured at baseline and after 6 months of treatment. RESULTS: Estrogen decreased levels of COMP at 6 months compared to baseline levels (–8.35 ± 19.38%), whereas the bisphosphonate and control groups resulted in no significant changes (–5.50 ± 18.69 and –1.49 ± 25.34%, respectively). Concentrations of osteocalcin decreased significantly in both treatment groups (estrogen –25.60 ± 24.42% and alendronate –13.76 ± 23.89%, respectively). There was a significant positive correlation between changes after 6 months in COMP and osteocalcin (R = 0.48, p = 0.002). CONCLUSIONS: Postmenopausal women treated with estrogen showed significantly decreased levels of COMP after 6 months. Estrogen might provide a further treatment modality in the prevention of joint destruction.
Full Text
http://www.karger.com/Article/FullText/339934
DOI
22964967
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Seo, Seok Kyo(서석교) ORCID logo https://orcid.org/0000-0003-3404-0484
Yang, Hyo In(양효인)
Lee, Byung Seok(이병석) ORCID logo https://orcid.org/0000-0001-6001-2079
Lim, Kyung Jin(임경진)
Jeon, Young Eun(전영은)
Cho, Si Hyun(조시현) ORCID logo https://orcid.org/0000-0003-2718-6645
Choi, Young Sik(최영식) ORCID logo https://orcid.org/0000-0002-1157-4822
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/90327
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse